← Leaderboards
Zsuzsanna Kinga Zsengeller
Inotek Pharmaceuticals Corporation
$1,107,155
Attributed
$1,107,155
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $262.8K · FY2013–25$500K$375K$250K$125K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,107,155 · 4
By mechanism
R43$638,615 · 3
R21$468,540 · 1
Top collaborators
No co-investigators on record.
Most similar at Inotek Pharmaceuticals Corporation
Same institution · by research overlap
- Andrew L Salzman$19,918,828
- Pal Pacher$214,161
- Alex Nivorozhkin$186,183
Others in their field
Top investigators on “Antioxidants”
- Gervasio A Lamas · Mount Sinai Medical Center (Miami Beach)$31,629,832
- Merit E Cudkowicz · Massachusetts General Hospital$31,059,060
- John James McNeil · Hennepin Healthcare Research Institute$28,037,648
- Walter C. Willett · Harvard University (Sch Of Public Hlth)$25,007,335
- Habibul Ahsan · Columbia University Health Sciences$21,519,304
- Michael A Schwarzschild · Massachusetts General Hospital$20,511,375
Research focus
AntioxidantsAdenovirusesBlood VesselsDisease /Disorder ModelAngiogenesis InhibitorsAngiogenic FactorComplicationAffect3-NitrotyrosineDesignBiological AvailabilityBiological MarkersBlood PressureBlood Pressure MedicationDoseBrain Hypoxia-IschemiaCandidate SelectionCanis FamiliarisCatalystCellsBiologicalClinical CandidateCollaborationsDrug Candidate
Grant awards (5)
Restoration of reduced nitric oxide bioavailability in Preeclampsia$205,732
R21 · FY2025 · HD · contact PI
Restoration of reduced nitric oxide bioavailability in Preeclampsia$262,808
R21 · FY2024 · HD · contact PI
Radiocontrast Nephropathy: Redox Degradation Catalyst and Nitric Oxide Donor$245,133
R43 · FY2013 · DK · contact PI
Organophosphate intoxication: effect of PARS inhibition$240,309
R43 · FY2004 · ES
Novel xanthine oxidase inhibitor for arthritis$153,173
R43 · FY2004 · AR